These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 12474310)

  • 21. Stimulation programs for pediatric drug research--do children really benefit?
    Boots I; Sukhai RN; Klein RH; Holl RA; Wit JM; Cohen AF; Burggraaf J
    Eur J Pediatr; 2007 Aug; 166(8):849-55. PubMed ID: 17225950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.
    Martin SD; Libretto SE; Pratt DJ; Brewin JS; Huq ZU; Saleh BT
    Curr Med Res Opin; 2003; 19(4):298-305. PubMed ID: 12841922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey.
    Deurell M; Weischer M; Pagsberg AK; Labianca J
    Nord J Psychiatry; 2008; 62(6):472-80. PubMed ID: 18841508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia.
    Mori K; Nagao M; Yamashita H; Morinobu S; Yamawaki S
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):659-65. PubMed ID: 15276691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
    Linden M; Scheel T; Eich FX
    J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
    Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
    Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meeting everyday challenges: antipsychotic therapy in the real world.
    Gorwood P
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S156-62. PubMed ID: 16872807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cooperation between office-based medical practices and hospitals in the treatment of schizophrenia in children and adolescents].
    Ott G; Bowi U
    Z Arztl Fortbild Qualitatssich; 2002 Oct; 96(9):587-96. PubMed ID: 12474309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pathologic manifestations in children whose parents are ill with schizophrenia].
    Butorina NE
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1976; 76(10):1530-5. PubMed ID: 998096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Misdiagnosis of first onset schizophrenia in adolescents].
    Braun-Scharm H
    Fortschr Med Orig; 2001; 119(1):45-8. PubMed ID: 11935658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prediction of the clinical efficacy of neuroleptics in the treatment of acute schizophrenic psychoses by assessment of the phenomenon of appearance of plaque in the blood].
    Preradović M
    God Vojnomed Akad; 1986; 28():45-9. PubMed ID: 2895725
    [No Abstract]   [Full Text] [Related]  

  • 32. [Changes in surface tension, electric potentials and acetylcholinesterase activity in the blood of children with schizophrenic psychoses treated with neuroleptics].
    Bichoński R; Dabrowski Z; Pawełek J; Gut W
    Folia Med Cracov; 1984; 25(1-2):73-86. PubMed ID: 6149984
    [No Abstract]   [Full Text] [Related]  

  • 33. [A stimulus barrier model of early onset schizophrenia: an integrative etiological and therapeutic approach].
    Eggers C
    Prax Kinderpsychol Kinderpsychiatr; 1998 Dec; 47(10):740-53. PubMed ID: 9889564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of older and newer neuroleptics for the treatment of schizophrenia.
    Hormaechea JA; García LE; Prieto L; Gómez JC
    Expert Rev Neurother; 2001 Nov; 1(2):161-70. PubMed ID: 19811028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of neuroleptics on the changes in interphase potential and acetylcholinesterase (E.C. 3.1.1.7) activity in the blood of children with schizophrenic psychoses].
    Bichoński R
    Psychiatr Pol; 1983; 17(5-6):375-82. PubMed ID: 6669657
    [No Abstract]   [Full Text] [Related]  

  • 36. Unlicensed and off label drug use for children with child psychiatric problems.
    Fitzgerald M
    Ir Med J; 1999 Mar; 92(2):284. PubMed ID: 10360114
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacotherapy for Children and Adolescents.
    Weber LT
    Dtsch Arztebl Int; 2023 Jun; 120(25):423-424. PubMed ID: 37661332
    [No Abstract]   [Full Text] [Related]  

  • 38. [Specific features and problems in the pharmacotherapy of schizophrenic psychoses in children and adolescents].
    Fegert JM
    Z Arztl Fortbild Qualitatssich; 2002 Oct; 96(9):597-603. PubMed ID: 12474310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions.
    Gaebel W; Riesbeck M; Janssen B; Schneider F; Held T; Mecklenburg H; Sass H
    Eur Arch Psychiatry Clin Neurosci; 2003 Aug; 253(4):175-84. PubMed ID: 12910348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.